The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors
Volume: 384, Issue: 12, Pages: 1168 - 1170
Published: Mar 25, 2021
Abstract
Immune Checkpoint Inhibitors and Tumor Mutational Burden The FDA has approved immune checkpoint inhibitors for solid tumors of any histologic origin with more than 10 mutations per megabase of...
Paper Details
Title
The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors
Published Date
Mar 25, 2021
Volume
384
Issue
12
Pages
1168 - 1170
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History